[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370708-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370708-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-indications-of-pembrolizumab-in-eight-common-cancers-current-evidence-and-future-directions","Therapeutic Indications of Pembrolizumab in Eight Common Cancers - Current Evidence and Future Directions","","Pembrolizumab is a monoclonal antibody that blocks the programmed death-1 (PD-1) pathway and has become increasingly integrated into cancer treatment strategies. Since its initial melanoma approval in 2014, numerous trials have assessed its efficacy and safety across cancers. This review summarizes therapeutic progress with pembrolizumab in eight cancers with poor prognosis, reports FDA approvals, and highlights active trials and research directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-indications-of-pembrolizumab-in-eight-common-cancers-current-evidence-and-future-directions/370708/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-indications-of-pembrolizumab-in-eight-common-cancers-current-evidence-and-future-directions/370708.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does pembrolizumab work in cancer therapy?","Question",{"text":63,"@type":64},"Pembrolizumab is a monoclonal antibody that inhibits the PD-1 receptor pathway, blocking PD-1/PD-L1 interactions to restore anti-tumor immune activity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What types of cancers are covered in this review?",{"text":68,"@type":64},"The review discusses therapeutic advances with pembrolizumab in eight common cancers associated with relatively poor prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What future research needs are highlighted?",{"text":72,"@type":64},"Future efforts should focus on biomarkers to better identify patients likely to respond and on new combination strategies to overcome immunotherapy resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370708,1791333802,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Reports  \nREVIEW  OPEN ACCESS   \nTherapeutic Indications of Pembrolizumab in Eight  \nCommon Cancers: Current Evidence and Future Directions  \nRaghed Mansour1,2  | Alghaidaq Shreba1,2  | Karam Khaddour3  | Michael Georgeos2,4 | Zuheir Alshehabi2,5  \n1Faculty of Medicine, Tishreen University, Lattakia, Syrian Arab Republic | 2Cancer Research Center, Tishreen University, Lattakia, Syrian Arab Republic | 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA | 4Department of Oncology, Tishreen University  \nHospital, Lattakia, Syrian Arab Republic | 5Department of Pathology, Tishreen University Hospital, Lattakia, Syrian Arab Republic Correspondence: Raghed Mansour ([raghedmansour94@gmail.com](raghedmansour94@gmail.com))  \nReceived: 4 May 2024 | Revised: 13 February 2025 | Accepted: 11 May 2025  \nFunding: The authors received no specific funding for this work.  \nKeywords: cancer treatment | immune checkpoint inhibitor | immunotherapy | pembrolizumab | therapeutic indications  \nABSTRACT  \nBackground: Pembrolizumab is a monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor pathway, which has increasingly been implicated in cancer treatment regimens. Since its first approval for melanoma in 2014, many trials have investigated the efficacy and safety of this new drug in different cancers. In this review, we discuss the therapeutic advances achieved with pembrolizumab in the management of eight cancers that are associated with a relatively poor prognosis. We also report the FDA approvals of this drug, highlighting promising ongoing trials and potential aspects for future research.  \nRecent Findings: Numerous trials have demonstrated robust anti-cancer effects, high response rates, and a favorable safety profile of pembrolizumab monotherapy or its combination in different lines and treatment settings. With the encouraging survival benefits of this treatment in advanced/metastatic disease, there has been an increasing tendency to explore its therapeutic potential in early-stage disease. Thus, pembrolizumab was effectively added to the standard neoadjuvant chemotherapy regimen for resectable TNBC and NSCLC, followed by adjuvant pembrolizumab monotherapy after resection. Similar positive results were found with the adjuvant administration of pembrolizumab after surgery in resectable RCC and melanoma. Pembrolizumab has also been recently studied in locally advanced resectable gastric and gastroesophageal junction adenocarcinoma as well as early-stage estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer as a neoadjuvantadjuvant regimen.  \nConclusions: The advent of immunotherapeutic agents such as pembrolizumab has unprecedently altered cancer therapy regimens; however, future research efforts should address the need for biomarkers that could better identify patients who would most likely respond to such therapy and investigate new combinations that could overcome resistance to immunotherapy.  \n1 | Introduction  \nPembrolizumab, a humanized monoclonal antibody that blocks programmed death receptor-1 (PD-1), was first introduced in 2014 as a new option for melanoma patients with metastatic disease that had progressed on prior therapy [1] . Soon after, Le et al. [2] established the benefit of mismatch-repair  \nstatus in predicting efficacy outcomes for immune checkpoint blockade with pembrolizumab, as somatic mutations that frequently occur in microsatellite instability-high (MSI-H) cancers were hypothesized to generate immunogenic antigens that potentiate immune response. Evidence supporting this finding accumulated for both colorectal [3] and noncolorectal [4] cancers and eventually outlined the approval  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Cancer Reports published b","cbCaig5cJe77q7Gg","https://ap.wps.com/l/cbCaig5cJe77q7Gg","pdf",647587,18,"English","# ABSTRACT\n## Background\n## Recent Findings\n## Conclusions\n# Introduction","[{\"question\":\"How does pembrolizumab work in cancer therapy?\",\"answer\":\"Pembrolizumab is a monoclonal antibody that inhibits the PD-1 receptor pathway, blocking PD-1/PD-L1 interactions to restore anti-tumor immune activity.\"},{\"question\":\"What types of cancers are covered in this review?\",\"answer\":\"The review discusses therapeutic advances with pembrolizumab in eight common cancers associated with relatively poor prognosis.\"},{\"question\":\"What future research needs are highlighted?\",\"answer\":\"Future efforts should focus on biomarkers to better identify patients likely to respond and on new combination strategies to overcome immunotherapy resistance.\"}]","Therapeutic Indications of Pembrolizumab in Eight Common Cancers - Current Evidence and Future Directions | PDF",1790189987,45]